Clinical-stage biotech company founded by serial entrepreneurs and owned by private & institutional investors. Discovery and development of new chemical entities with strong IP and worldwide rights targeting big market indications in immunology and oncology. After successful proof-of-concept studies in early clinical phases, seeking license agreements with pharmaceutical companies for further clinical development and commercialization. ---- PIPELINE: ---- Two of Oncostellae's drug candidates have reached advanced development stages and are currently being evaluated in clinical studies in patients: OST-122 is a safe, non-systemic JAK inhibitor for the treatment of Ulcerative Colitis (Phase 2a), and OST-499 is a GR antagonist for the treatment of colon cancer and other solid tumors (Phase 1). Positive data on safety and efficacy that are expected to be available by the end of 2023 would provide outlicensing opportunities.